Prestige Consumer Healthcare Inc(PBH) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Oct 30 at 4:00 PM ET (Korea 10/31 05:00)
Full metrics table
| Index | RUT | P/E | 13.74 | EPS (ttm) | 3.57 | Insider Own | 1.47% | Shs Outstand | 47.4M | Perf Week | 2.64% |
| Market Cap | 2.32B | Forward P/E | 9.56 | EPS next Y | 11.95% | Insider Trans | -0.32% | Shs Float | 46.7M | Perf Month | 9.58% |
| Enterprise Value | 4.30B | PEG | 1.39 | EPS next Q | 1.07 | Inst Own | 115.6% | Short Float | 8.49% | Perf Quarter | -5.51% |
| Income | 0.17B | P/S | 2.1 | EPS this Y | 4.66% | Inst Trans | 4.09% | Short Ratio | 7.06 | Perf Half Y | -10.95% |
| Sales | 1.10B | P/B | 1.21 | EPS next 5Y | 6.86% | ROA | 4.3% | Short Interest | 3.96M | Perf YTD | -20.47% |
| Book/sh | 40.46 | P/C | 26.08 | EPS past 3/5Y | - 3.72% | ROE | 9.12% | 52W High | -30.97% ($71.07) | Perf Year | -18.6% |
| Cash/sh | 1.88 | P/FCF | 9.88 | Sales past 3/5Y | -1.17% 2.91% | ROIC | 4.34% | 52W Low | 15.11% ($42.62) | Perf 3Y | -16.73% |
| Dividend Est. | - | EV/EBITDA | 13.34 | EPS Y/Y TTM | -16.45% | Gross Margin | 51.59% | Volatility(W/M) | 2.71% 2.85% | Perf 5Y | -18.22% |
| Dividend TTM | - | EV/Sales | 3.89 | Sales Y/Y TTM | -1.36% | Oper. Margin | 26.26% | ATR (14) | 1.48 | Perf 10Y | 7.07% |
| Dividend Ex-Date | 2013/12/27 | Quick Ratio | 1.99 | EPS Q/Q | -35.65% | Profit Margin | 15.57% | RSI (14) | 54.14 | Recom | 1.71 |
| Dividend Gr. 3/5Y | - | Current Ratio | 3.23 | Sales Q/Q | 6.48% | SMA20 | 1.56% ($48.31) | Beta | 0.32 | Target Price | $67.25 |
| Payout | - | Debt/Eq | 1.08 | Earnings | 2026/11/5 | SMA50 | 1.09% ($48.53) | Rel Volume | 0.66 | Prev Close | $48.75 |
| Employees | 890 | LT Debt/Eq | 1.07 | EPS/Sales Surpr. | 9.64% 5.01% | SMA200 | -9.3% ($54.09) | Avg Volume(3M) | 0.56M | Price | $49.06 |
| IPO | 2005/2/10 | Option/Short | Yes/Yes | Trades | 5818 | Volume | 371,501 | Change | 0.64% |
This is a U.S. company that owns and sells over-the-counter (OTC) drugs and consumer health care brands. It operates a diverse portfolio of non-prescription health and wellness brands, generating stable revenue through well-known names spanning categories such as eye care, digestive health, feminine care, and pain relief. The company is a consumer health care operator that grows through brand acquisitions and marketing.
Over the past 1 year, on the lower side
31% below its 1-year high.
Traded less than usual. That is 66% of its average volume.
Next earnings report: November 5
3 days to go.
PBH makes money exceptionally well
Of every $100 in sales, $26.26 is kept as operating profit.
Tap to view numbers
Growth is moderate
Earnings are expected to grow by +4.7% this year.
Tap to view numbers
The price is about the industry average
For a company expected to earn $100 next year, you would pay $956. Peers typically go for $1,519. Compared with its own 4-year average, it is 12% cheaper now.
Tap to view numbers
Results have missed expectations
Frequently misses analyst estimates
Tap to view numbers
The outlook is positive
Analyst sentiment is Buy.
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -18.2%. The S&P 500 did +65% over the same period.
Tap to view numbers
No dividend
It reinvests profits in the business instead of paying dividends.
Ownership looks stable
Institutions hold 115.6%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
It ranks #21 of 83 in the industry
Based on market cap of $2B.
SUPN#20 Supernus Pharmaceuticals Inc $2B PER - PBH#21 Prestige Consumer Healthcare Inc $2B PER 13.7 
HCM#22 HUTCHMED (China) Limited ADR $2B PER 129.3 
PRGO#23 Perrigo Company plc $2B PER - 
BCRX#24 Biocryst Pharmaceuticals Inc $2B PER - 
FAQ
What kind of company is PBH?
PBH belongs to the Healthcare sector and operates in the Drug Manufacturers - Specialty & Generic industry.
What is the market cap of PBH?
The market cap of PBH is approximately $2.3B, ranking 1,945 within its sector.
What is the P/E ratio of PBH?
PBH has a P/E ratio of approximately 13.7x, which can be used to assess its valuation relative to the Healthcare sector average.
What is the 52-week high and low for PBH?
PBH has recorded a 52-week high of $71.07 and a low of $42.62.
